Drug intelligence / Profile preview

CC-3

Development stage: Phase 1
Lead developer: German Cancer Research Center
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CC-3 is a bispecific T-cell engager (BiTE) antibody with CD276xCD3 specificity. It has a dual mechanism of action, binding to CD276 on cancer cells and tumor vessels of colorectal cancer while also binding to CD3 on T cells. CC-3 was developed in a novel format that prolongs serum half-life and reduces off-target T cell activation, potentially resulting in fewer side effects. The optimized format allows for application of effective doses with expected high anticancer activity.

Targets

CD3 (T-cell surface glycoprotein CD3)B7-H3

Beyond the preview

Go deeper on CC-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC-3.

Explore the full profile